Biogen wins ruling in Tecfidera IP case; shares rise

NEW YORK (Reuters) - Biogen Inc on Tuesday won an intellectual property rights ruling against hedge fund manager Kyle Bass over its top multiple sclerosis pill, Tecfidera, pushing shares up more than 1 percent on a day when most U.S. stocks were down.